Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 5, 2008, Pages 242-247

  Lainesse, Audrey ^a   Hussain, Saleh ^a   Monif, Tausif ^b,d   Reyar, Simrit ^b   Tippabhotla, Sudhakar Koundinya ^b   Madan, Ashish ^b   Thudi, Nageshwar Rao ^c  

^a Anapharm Canada   (Canada)

^b Ranbaxy Laboratories Limited   (India)

^c Ranbaxy Pharmaceuticals Canada Inc   (Canada)

^d RANBAXY LABORATORIES LTD   (India)

Author keywords

CAS 104987 11 3; Immunosuppressants; Tacrolimus, bioequivalence, fasting and fed condition, male and females volunteers, pharmacokinetics

Indexed keywords

CAS 104987 11 3; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FOOD INTAKE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

EID: 44849119510     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296500     Document Type: Article

References (16)

1. Prograf (tacrolimus) prescribing information. Deerfield (IL): Astellas Pharma US, Inc., revised Apr 2006.
2. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-97.
3. Plosker GL, Foster RH. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 200 ;5:323-89.
4. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623-53.
5. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-30.
6. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit. 2005;27:422-30.
7. Sabatini S, Ferguson RM, Helderman JH, Hulla R ; Kirkpatrick BS; Barr WH. Drug substitution in transplantation: a National Kidney Foundation white paper. Am J Kidney Dis. 1999;33:389-397.
8. Committee for Proprietary Medicinal Products. Note for guidance on investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). London, 26 Jul 2001. Available at: http://www.emea.europa.eu/pdfs/human/ewp/ 140198en.pdf.
9. Center for Drug Evaluation and Research (CDER), US FDA. Industry Guidance, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Rockville, Mar 2003. Available at: http://www.fda.gov/cder/guidance/5356fnl.pdf.
10. Bekersky I, Dressler D, Colburn W, Mekki Q. Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design. J Clin Pharmacol. 1999;39:1032-1037.
11. Bekersky I, Dressler D, Boswell GW, Fergen B, Tracewell W, Mekki Q. Bioequivalence of a New Strength Tacrolimus Capsule under Development. Transplant Proc.1938;30:1457-1459.
12. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl. 2000;748:41-53.
13. Lee JW, Sukovaty RL, Farmen RH, Dressler DE, Alak A, Bekersky I. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. Ther Drug Monit. 1997;19:201-207.
14. Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther. 2001;69:24-31.
15. Nightengale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987;258:1200-1204.
16. American Pharmaceutical Association. Substitution of Critical Dose Drugs: Issues, Analysis, and Decision Making. 2000. Available at: http://www. pharmacist.com/pdf/critical_dose.pdf.